US OptionsDetailed Quotes
MIRM250117C70000
- 0.00
- 0.000.00%
15min DelayClose Dec 24 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest70.00Strike Price0.00Turnover0.00%IV65.99%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma8.61Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Mirum Pharmaceuticals Stock Discussion
$Ionis Pharmaceuticals (IONS.US)$ : 🤔
⇨ IONIS-APOCIII-LRx (Olezarsen)
‣ FCS (Familial chylomicronemia syndrome)
‣ PDUFA: 12/19/24 (NDA)
🗓️ Last Week’s PDUFA Decisions:
$Checkpoint Therapeutics (CKPT.US)$ : Approved 12/13/24 ✅
⇨ UNLOXCYT (cosibelimab-ipdl)
‣ metastatic or locally advanced cSCC (cutaneous squamous cell carcinoma)
‣ PDUFA: 12/28/24 (resubmitted BLA)
$Neurocrine Biosciences (NBIX.US)$ : Approved 12/13/24 ✅
⇨ CRENESSITY™ (crin...
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont oral solution
$BeiGene (BGNE.US)$ ⇨ Tisleli...
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinece...
PROS-IPO on Jul 2019; triple digit on recent quarterly sales; ADR6.4%; dollar average volume>10MM; interesting volume; ATH; RS rating=89; near time high.
CONS-might need to wait for 10MA to catch up.
$iLearningEngines (AILE.US)$
PROS-IPO on Apr 2024 after business combination; AI theme; ADR12.33%; price increased approximately 90% in 1 month and sideway consolidate, building higher low and surphing 10 MA; vol drying up.
CONS-dollar volume between 1MM to 5...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$BeiGene (BGNE.US)$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb (BMY.US)$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals (VNDA.US)$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia (EYEN.US)$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
$Eyenovia (EYEN.US)$ $Vanda Pharmaceuticals (VNDA.US)$ $Mirum Pharmaceuticals (MIRM.US)$ $Madrigal Pharmaceuticals (MDGL.US)$ $Geron (GERN.US)$ $Bristol-Myers Squibb (BMY.US)$ $2seventy bio (TSVT.US)$ $Legend Biotech (LEGN.US)$ $OptiNose (OPTN.US)$ $Orchard Therapeutics (ORTX.US)$ $Merck & Co (MRK.US)$ $Akebia Therapeutics (AKBA.US)$ $AstraZeneca (AZN.US)$ $Liquidia (LQDA.US)$ $Esperion Therapeutics (ESPR.US)$ $Regeneron Pharmaceuticals (REGN.US)$ $BeiGene (BGNE.US)$
$Mirum Pharmaceuticals (MIRM.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Geron (GERN.US)$
$Bristol-Myers Squibb (BMY.US)$
$Legend Biotech (LEGN.US)$
$2seventy bio (TSVT.US)$
$OptiNose (OPTN.US)$
No comment yet